In addition, originators may claim a risk premium to reflect possible failures in initial testing over time. Finally, the system may also provide an obligation by generic producers to pay compensation to the data originator for the benefit of early market entry (as compared to the amount of time needed in case of independent replication of clinical trials). Costs incurred to prepare the clinical test data file for the DRA may therefore differ from those costs incurred for the preparation of the patent application with the patent office.